Synthesis and biological evaluation of the first dual tyrosyl-DNA phosphodiesterase i (Tdp1)-topoisomerase i (Top1) inhibitors

Trung Xuan Nguyen, Andrew Morrell, Martin Conda-Sheridan, Christophe Marchand, Keli Agama, Alun Bermingam, Andrew G. Stephen, Adel Chergui, Alena Naumova, Robert Fisher, Barry R. O'Keefe, Yves Pommier, Mark Cushman

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Substances with dual tyrosyl-DNA phosphodiesterase I-topoisomerase I inhibitory activity in one low molecular weight compound would constitute a unique class of anticancer agents that could potentially have significant advantages over drugs that work against the individual enzymes. The present study demonstrates the successful synthesis and evaluation of the first dual Top1-Tdp1 inhibitors, which are based on the indenoisoquinoline chemotype. One bis(indenoisoquinoline) had significant activity against human Tdp1 (IC 50 = 1.52 ± 0.05 μM), and it was also equipotent to camptothecin as a Top1 inhibitor. Significant insights into enzyme-drug interactions were gained via structure-activity relationship studies of the series. The present results also document the failure of the previously reported sulfonyl ester pharmacophore to confer Tdp1 inhibition in this indenoisoquinoline class of inhibitors even though it was demonstrated to work well for the steroid NSC 88915 (7). The current study will facilitate future efforts to optimize dual Top1-Tdp1 inhibitors.

Original languageEnglish (US)
Pages (from-to)4457-4478
Number of pages22
JournalJournal of Medicinal Chemistry
Volume55
Issue number9
DOIs
StatePublished - May 10 2012

Fingerprint

4-pregnen-21-ol-3,20-dione-21-(4-bromobenzenesufonate)
Phosphodiesterase I
Camptothecin
Type I DNA Topoisomerase
Enzymes
Structure-Activity Relationship
Drug Interactions
Human Activities
Antineoplastic Agents
Esters
Molecular Weight
Steroids
Pharmaceutical Preparations
tyrosyl-DNA phosphodiesterase

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Synthesis and biological evaluation of the first dual tyrosyl-DNA phosphodiesterase i (Tdp1)-topoisomerase i (Top1) inhibitors. / Nguyen, Trung Xuan; Morrell, Andrew; Conda-Sheridan, Martin; Marchand, Christophe; Agama, Keli; Bermingam, Alun; Stephen, Andrew G.; Chergui, Adel; Naumova, Alena; Fisher, Robert; O'Keefe, Barry R.; Pommier, Yves; Cushman, Mark.

In: Journal of Medicinal Chemistry, Vol. 55, No. 9, 10.05.2012, p. 4457-4478.

Research output: Contribution to journalArticle

Nguyen, TX, Morrell, A, Conda-Sheridan, M, Marchand, C, Agama, K, Bermingam, A, Stephen, AG, Chergui, A, Naumova, A, Fisher, R, O'Keefe, BR, Pommier, Y & Cushman, M 2012, 'Synthesis and biological evaluation of the first dual tyrosyl-DNA phosphodiesterase i (Tdp1)-topoisomerase i (Top1) inhibitors', Journal of Medicinal Chemistry, vol. 55, no. 9, pp. 4457-4478. https://doi.org/10.1021/jm300335n
Nguyen, Trung Xuan ; Morrell, Andrew ; Conda-Sheridan, Martin ; Marchand, Christophe ; Agama, Keli ; Bermingam, Alun ; Stephen, Andrew G. ; Chergui, Adel ; Naumova, Alena ; Fisher, Robert ; O'Keefe, Barry R. ; Pommier, Yves ; Cushman, Mark. / Synthesis and biological evaluation of the first dual tyrosyl-DNA phosphodiesterase i (Tdp1)-topoisomerase i (Top1) inhibitors. In: Journal of Medicinal Chemistry. 2012 ; Vol. 55, No. 9. pp. 4457-4478.
@article{e9309ba7788d498290396ba80978acf1,
title = "Synthesis and biological evaluation of the first dual tyrosyl-DNA phosphodiesterase i (Tdp1)-topoisomerase i (Top1) inhibitors",
abstract = "Substances with dual tyrosyl-DNA phosphodiesterase I-topoisomerase I inhibitory activity in one low molecular weight compound would constitute a unique class of anticancer agents that could potentially have significant advantages over drugs that work against the individual enzymes. The present study demonstrates the successful synthesis and evaluation of the first dual Top1-Tdp1 inhibitors, which are based on the indenoisoquinoline chemotype. One bis(indenoisoquinoline) had significant activity against human Tdp1 (IC 50 = 1.52 ± 0.05 μM), and it was also equipotent to camptothecin as a Top1 inhibitor. Significant insights into enzyme-drug interactions were gained via structure-activity relationship studies of the series. The present results also document the failure of the previously reported sulfonyl ester pharmacophore to confer Tdp1 inhibition in this indenoisoquinoline class of inhibitors even though it was demonstrated to work well for the steroid NSC 88915 (7). The current study will facilitate future efforts to optimize dual Top1-Tdp1 inhibitors.",
author = "Nguyen, {Trung Xuan} and Andrew Morrell and Martin Conda-Sheridan and Christophe Marchand and Keli Agama and Alun Bermingam and Stephen, {Andrew G.} and Adel Chergui and Alena Naumova and Robert Fisher and O'Keefe, {Barry R.} and Yves Pommier and Mark Cushman",
year = "2012",
month = "5",
day = "10",
doi = "10.1021/jm300335n",
language = "English (US)",
volume = "55",
pages = "4457--4478",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "9",

}

TY - JOUR

T1 - Synthesis and biological evaluation of the first dual tyrosyl-DNA phosphodiesterase i (Tdp1)-topoisomerase i (Top1) inhibitors

AU - Nguyen, Trung Xuan

AU - Morrell, Andrew

AU - Conda-Sheridan, Martin

AU - Marchand, Christophe

AU - Agama, Keli

AU - Bermingam, Alun

AU - Stephen, Andrew G.

AU - Chergui, Adel

AU - Naumova, Alena

AU - Fisher, Robert

AU - O'Keefe, Barry R.

AU - Pommier, Yves

AU - Cushman, Mark

PY - 2012/5/10

Y1 - 2012/5/10

N2 - Substances with dual tyrosyl-DNA phosphodiesterase I-topoisomerase I inhibitory activity in one low molecular weight compound would constitute a unique class of anticancer agents that could potentially have significant advantages over drugs that work against the individual enzymes. The present study demonstrates the successful synthesis and evaluation of the first dual Top1-Tdp1 inhibitors, which are based on the indenoisoquinoline chemotype. One bis(indenoisoquinoline) had significant activity against human Tdp1 (IC 50 = 1.52 ± 0.05 μM), and it was also equipotent to camptothecin as a Top1 inhibitor. Significant insights into enzyme-drug interactions were gained via structure-activity relationship studies of the series. The present results also document the failure of the previously reported sulfonyl ester pharmacophore to confer Tdp1 inhibition in this indenoisoquinoline class of inhibitors even though it was demonstrated to work well for the steroid NSC 88915 (7). The current study will facilitate future efforts to optimize dual Top1-Tdp1 inhibitors.

AB - Substances with dual tyrosyl-DNA phosphodiesterase I-topoisomerase I inhibitory activity in one low molecular weight compound would constitute a unique class of anticancer agents that could potentially have significant advantages over drugs that work against the individual enzymes. The present study demonstrates the successful synthesis and evaluation of the first dual Top1-Tdp1 inhibitors, which are based on the indenoisoquinoline chemotype. One bis(indenoisoquinoline) had significant activity against human Tdp1 (IC 50 = 1.52 ± 0.05 μM), and it was also equipotent to camptothecin as a Top1 inhibitor. Significant insights into enzyme-drug interactions were gained via structure-activity relationship studies of the series. The present results also document the failure of the previously reported sulfonyl ester pharmacophore to confer Tdp1 inhibition in this indenoisoquinoline class of inhibitors even though it was demonstrated to work well for the steroid NSC 88915 (7). The current study will facilitate future efforts to optimize dual Top1-Tdp1 inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=84861078122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861078122&partnerID=8YFLogxK

U2 - 10.1021/jm300335n

DO - 10.1021/jm300335n

M3 - Article

C2 - 22536944

AN - SCOPUS:84861078122

VL - 55

SP - 4457

EP - 4478

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 9

ER -